Mechanisms of the deleterious effects of tamoxifen on mitochondrial respiration rate and phosphorylation efficiency

Toxicology and Applied Pharmacology

Volumn 176, Issue 3, 2001, Pages 145-152

  Cardoso, Carla M P ^a,b   Custódio, José B A ^a,b   Almeida, Leonor M ^a,b   Moreno, António J M ^b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Anticancer drug; Membrane disruption; Mitochondria; Mitochondrial proton leak; Mitochondrial transmembrane potential; Respiration rate; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

ANIMAL CELL; ARTICLE; BREAST CANCER; CELL DEATH; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; GROWTH INHIBITION; LIVER MITOCHONDRION; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL RESPIRATION; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; TUMOR GROWTH;

EID: 0035516835     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.2001.9265     Document Type: Article

References (47)

1. Tamoxifen inhibits acidification in cells independent of the estrogen receptor
2. A phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer
3. The proton leak across the mitochondrial inner membrane
4. Stimulation of the electron transport chain in mitochondria isolated from rats treated with mannoheptulose or glucagon
5. The respiration chain and oxidative phosphorylation
6. Tamoxifen and its active metabolite inhibit growth of estrogen receptor-negative MDA-MB-435 cells
7. A mechanism for tamoxifen-mediated inhibition of acidification
8. Tamoxifen and metabolites in MCF-7 cells: Correlation between binding to estrogen receptor and inhibition of cell growth
9. Clinical and radiographic response in patients with recurrent malignant gliomas treated with high-dose tamoxifen
10. Tamoxifen inhibits growth of oestrogen receptor-negative A549 cells
11. Hemolysis of human erythrocytes induced by tamoxifen is related to disruption of membrane structure
12. A reliable and rapid procedure to estimate drug partitioning in biomembranes
13. The anti-cancer drug tamoxifen induces changes in the physical properties of model and native membranes
14. Tamoxifen and hydroxytamoxifen as intramembraneous inhibitors of lipid peroxidation. Evidence for peroxyl radical scavenging activity
15. The effect of the anti-cancer drugs tamoxifen and hydroxytamoxifen on the calcium pump of isolated sarcoplasmic reticulum vesicles
16. 2+ and inorganic phosphate
17. Tamoxifen but not 4-hydroxytamoxifen initiates apoptosis in p53(-) normal human mammary epithelial cells by inducing mitochondrial depolarization
18. Interactions of 2,2-bis(p-chlorophenyl)-1,1-dichloroethylene with mitochondrial oxidative phosphorylation
19. Dual effect of amiodarone on mitochondrial respiration. Initial protonophoric uncoupling effect followed by inhibition of the respiratory chain at the levels of complex I and complex II
20. Interaction of butylated hydroxyanisole with mitochondrial oxidative phosphorylation
21. Studies on the mechanism of uncoupling by amine local anesthetics. Evidence for mitochondrial proton transport mediated by lipophilic ion pairs
22. Determination of serum proteins by means of the biuret reaction
23. Altered relationship between proton motive force and the respiration rate in non-phosphorylating liver mitochondria isolated from rats of different thyroid hormone status
24. Hypothyroidism in rats decreases mitochondrial inner membrane cation permeability
25. Thyroid-hormone control of state 3 respiration in isolated rat liver mitochondria
26. Effect of proton motive force on the relative stoichiometries of the mitochondrial proton pumps
27. Inhibition of glutamate-induced mitochondrial depolarization by tamoxifen in cultured neurons
28. Phloretin: An uncoupler and an inhibitor of mitochondrial oxidative phosphorylation
29. Long-term adjuvant tamoxifen therapy for breast cancer
30. Membrane potential of mitochondria measured with an electrode sensitive to tetraphenylphosphonium and relationship between proton electrochemical potential and phosphorylation potential in steady state
31. 2+ uptake by the cardiac sarcoplasmic reticulum
32. Several nongenotoxic carcinogens uncouple mitochondrial oxidative phosphorylation
33. Effect of tamoxifen on regulation of viral replication and human immunodeficiency virus (HIV) long terminal repeat-directed transcription in cells chronically infected with HIV-1
34. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment
35. Changes in the hepatic mitochondrial respiratory system in the transition from weaning to adulthood in rats
36. Use of Bacillus stearothermophilus as a model to study tamoxifen-membrane interactions
37. Activation energies of the ATPase activity of sarcoplasmic reticulum
38. Mitochondrial bioenergetics as affected by DDT
39. Slip and leak in mitochondria oxidative phosphorylation
40. The control of the electron flux through cytochrome c oxidase
41. The lipophilic weak base (Z)-5-methyl-2-[2-(1-naphthyl)ethenyl]-4-piperidinopyridine (AU-1421) is a potent protonophore type cationic uncoupler of oxidative phosphorylation in mitochondria
42. Guidelines for monitoring patients taking tamoxifen treatment
43. Estimation of tamoxifen's efficiency for preventing the formation and growth of breast tumors
44. Tamoxifen induced membrane alterations in human breast cancer cells
45. Interaction of the anticancer drug tamoxifen with the human erythrocyte membrane and molecular models
46. Tamoxifen in the treatment of recurrent ovarian carcinoma
47. Mitochondria-mediated cell injury